
Sign up to save your podcasts
Or


On Biotech Hangout this week, hosts Daphne Zohar, Tim Opler, Chris Garabedian, Bruce Booth and Michal Preminger are joined by Andy Plump, President, Research & Development at Takeda, and Jay Bradner, Physician-Scientist and former President of the Novartis Institutes for BioMedical Research. They talk pharma productivity and its impact on M&A, new models for advancing and funding medicine and why we need them and what a pharmaceutical R&D head actually does. Andy and Jay discuss conflicts between research and commercial departments, share their experiences, insights and strategies learned from their careers in R&D executive roles and describe the elements needed for a biotech company to be successful long-term. The hosts end with a lively discussion of business models in the industry from venture creation to listed “truffle hunters” to pharma efforts at being more entrepreneurial.
By Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more4.4
1818 ratings
On Biotech Hangout this week, hosts Daphne Zohar, Tim Opler, Chris Garabedian, Bruce Booth and Michal Preminger are joined by Andy Plump, President, Research & Development at Takeda, and Jay Bradner, Physician-Scientist and former President of the Novartis Institutes for BioMedical Research. They talk pharma productivity and its impact on M&A, new models for advancing and funding medicine and why we need them and what a pharmaceutical R&D head actually does. Andy and Jay discuss conflicts between research and commercial departments, share their experiences, insights and strategies learned from their careers in R&D executive roles and describe the elements needed for a biotech company to be successful long-term. The hosts end with a lively discussion of business models in the industry from venture creation to listed “truffle hunters” to pharma efforts at being more entrepreneurial.

32,238 Listeners

538 Listeners

752 Listeners

125 Listeners

338 Listeners

61 Listeners

86 Listeners

35 Listeners

152 Listeners

64 Listeners

16 Listeners

12 Listeners

15 Listeners

8 Listeners

60 Listeners